• Pivotal (Validation) Trial surpasses key enrolment milestones
• Preparations to add acute ischaemia detection endpoint
• Successful First Responder aeromedical feasibility and usability study
• Received $2.0m in grant funding
• Maintained strong balance sheet with $17.1m in cash reserves

EMVision Medical Devices Ltd. has released its Quarterly Activities and Cash Flow Report for the period ending 30 June 2026. The report highlights significant progress in clinical and regulatory activities, financial performance, and strategic initiatives. Key achievements include surpassing key enrolment milestones in the Pivotal (Validation) Trial, preparations to add an acute ischaemia detection endpoint, successful completion of the First Responder aeromedical feasibility and usability study, and receipt of $2.0 million in grant funding. The company maintains a robust financial position with cash reserves of $17.1 million and $4.6 million in non-dilutive funding remaining under current grant programs. EMVision is well-positioned to advance its innovative neurodiagnostic technology, with multiple clinical studies in progress and a strong balance sheet supporting continued execution.

Received $2.0m in grant funding, cash reserves of $17.1m, $4.6m in non-dilutive funding

EMVision is preparing to add an acute ischaemia detection endpoint to the Pivotal (Validation) Trial, aiming to strengthen the emu¢ device's clinical and commercial value proposition.